Reuters logo
Bayer enters cancer research deal with Compugen
August 5, 2013 / 10:23 AM / 4 years ago

Bayer enters cancer research deal with Compugen

FRANKFURT, Aug 5 (Reuters) - German pharmaceuticals company Bayer AG has entered a new cancer partnership with Compugen Ltd to research, develop and commercialise antibody-based therapies.

The two partners will jointly carry out a preclinical research programme, they said in a statement on Monday.

Under the deal, Compugen will receive an upfront payment of $10 million, and is eligible to receive over $500 million in potential milestone payments.

Compugen may also receive mid to high single digit royalties on worldwide net sales of any resulting products under the collaboration.

“Antibody-based immunotherapies are promising approaches in oncology which can stimulate the body’s own immune cells to fight cancer cells,” Bayer executive Andreas Busch said in a statement. (Reporting by Victoria Bryan)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below